The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Troglitazone Improves Defects in Insulin Action, Insulin Secretion, Ovarian Steroidogenesis, and Fibrinolysis in Women with Polycystic Ovary Syndrome1
Abstract
Women with polycystic ovary syndrome (PCOS) are characterized by defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis. We administered the insulin-sensitizing agent troglitazone to 13 obese women with PCOS and impaired glucose tolerance to determine whether attenuation of hyperinsulinemia ameliorates these defects. All subjects had oligomenorrhea, hirsutism, polycystic ovaries, and hyperandrogenemia. Before and after treatment with troglitazone (400 mg daily for 12 weeks), all had 1) a GnRH agonist (leuprolide) test, 2) a 75-g oral glucose tolerance test, 3) a frequently sampled iv glucose tolerance test to determine the insulin sensitivity index and the acute insulin response to glucose, 4) an oscillatory glucose infusion to assess the ability of the beta-cell to entrain to glucose as quantitated by the normalized spectral power for the insulin secretion rate, and 5) measures of fibrinolytic capacity [plasminogen activator inhibitor type 1 (PAI-1) and tissue plasminogen activator]. There was no change in body mass index (39.9 +/- 1.4 vs. 40.2 +/- 1.4 kg/m2) or body fat distribution after treatment. Both the fasting (91 +/- 3 vs. 103 +/- 3 mg/dL; P < 0.001) and 2 h (146 +/- 8 vs. 171 +/- 6 mg/dL; P < 0.02) plasma glucose concentrations during the oral glucose tolerance test declined significantly. There was a concordant reduction in glycosylated hemoglobin to 5.7 +/- 0.1 from a pretreatment level of 6.1 +/- 0.1% (P < 0.03). Insulin sensitivity increased from 0.58 +/- 0.14 to 0.95 +/- 0.26 10(-5) min-1/pmol.L (P < 0.01) after treatment as did the disposition index (745 +/- 135 vs. 381 +/- 96; P < 0.05). The ability of the beta-cell to appropriately detect and respond to an oscillatory glucose infusion improved significantly after troglitazone treatment; the normalized spectral power for the insulin secretion rate increased to 5.9 +/- 1.1 from 4.3 +/- 0.8 (P < 0.05). Basal levels of total testosterone (109.3 +/- 15.2 vs. 79.4 +/- 9.8 ng/dL; P < 0.05) and free testosterone (33.3 +/- 4.0 vs. 21.2 +/- 2.6 pg/mL; P < 0.01) declined significantly after troglitazone treatment. Leuprolide-stimulated levels of 17-hydroxyprogesterone, androstenedione, and total testosterone were significantly lower posttreatment compared to pretreatment. The reduction in androgen levels occurred independently of any changes in gonadotropin levels. A decreased functional activity of PAI-1 in blood (from 12.7 +/- 2.8 to 6.3 +/- 1.4 AU/mL P < 0.05) was associated with a decreased concentration of PAI-1 protein (from 64.9 +/- 9.1 to 44.8 +/- 6.1 ng/mL; P < 0.05). No change in the functional activity of tissue plasminogen activator (from 5.3 +/- 0.4 to 5.1 +/- 0.5 IU/mL) was observed despite a decrease in its concentration (from 9.6 +/- 0.9 to 8.2 +/- 0.7 ng/mL; P < 0.05). The marked reduction in PAI-1 could be expected to improve the fibrinolytic response to thrombosis in these subjects. We conclude that administration of troglitazone to women with PCOS and impaired glucose tolerance ameliorates the metabolic and hormonal derangements characteristic of the syndrome. Troglitazone holds potential as a useful primary or adjunctive treatment for women with PCOS.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Low SHBG levels are also increased by insulin-sensitising medication (Ehrmann et al., 1997;Moghetti et al., 2000;Moran et al., 2013);”
From Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic–hyperinsulinaemic clamp studies (2016) · cites this paper as Ehrmann et al., 1997
Citations
Cites
Spectral Analysis and its Applications.
Freiberger, W. F., Jenkins, G. M., & Watts, D. G. (1969) · Journal of the American Statistical Association · doi:10.2307/2286100 · Cited by 4,981
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Morgan, C. R., & Lazarow, A. (1963) · Diabetes · doi:10.2337/diab.12.2.115 · Cited by 2,199
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967 · cited 2×
“It is important to note, however, that although insulin sensitivity improved in response to treatment, it remained profoundly depressed in these subjects and was disproportionate to the degree of obesity, as described previously ( 2 ).”
BackgroundBergman, R. N., Phillips, L. S., & Cobelli, C. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110398 · Cited by 1,640 · cited 3×
“Because the product of these measures is presumed to be constant ( 33 , 42, 43), a compensatory decrease in AIRg would be expected to accompany the increase in Si observed after troglitazone treatment.”
BackgroundMethodInfluentialMazess, R., Barden, H., Bisek, J., & Hanson, J. (1990) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/51.6.1106 · Cited by 1,476
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405 · cited 4×
“The product of Si and AIRg (disposition index) was also derived and provides a measure of b-cell secretory function adjusted for insulin sensitivity, previously described as a constant in any individual ( 43 ).”
BackgroundMethodInfluentialThiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes
Saltiel, A. R., & Olefsky, J. M. (1996) · Diabetes · doi:10.2337/diab.45.12.1661 · Cited by 1,053 · cited 1×
“Although the precise mechanism of action of troglitazone remains incompletely defined, it appears to enhance insulin action without directly stimulating insulin secretion ( 50 ) and acts as a selective ligand for the peroxisome proliferator-activated receptor-g (51).”
BackgroundToward Physiological Understanding of Glucose Tolerance: Minimal-Model Approach
Bergman, R. N. (1989) · Diabetes · doi:10.2337/diab.38.12.1512 · Cited by 1,001
Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism.
Adams, J., Polson, D. W., & Franks, S. (1986) · BMJ · doi:10.1136/bmj.293.6543.355 · Cited by 981 · cited 1×
“array sector vaginal probe (GE RT 3000, General Electric Corp., Milwaukee, WI) ( 27 ).”
BackgroundImprovement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone
Nolan, J. J., Ludvik, B., Beerdsen, P., Joyce, M., & Olefsky, J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411033311803 · Cited by 926 · cited 2×
“Troglitazone is a novel insulin-sensitizing agent that improves oral glucose tolerance and insulin resistance in individuals with impaired glucose tolerance (IGT) (23, 24 ).”
BackgroundResultCauter, E. V., Mestrez, F., Sturis, J., & Polonsky, K. S. (1992) · Diabetes · doi:10.2337/diab.41.3.368 · Cited by 890 · cited 1×
“These standard parameters were calculated from 200 decay curves of biosynthetic C peptide obtained in normal, obese, and NIDDM subjects ( 44 ).”
MethodSelf-citationEnhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeisty
Shimomura, I., Funahasm, T., Takahashi, M., Maeda, K., Kotani, K., Nakamura, T., Yamashita, S., Miura, M., Fukuda, Y., Takemura, K., et al. (1996) · Nature Medicine · doi:10.1038/nm0796-800 · Cited by 890
Nestler, J. E., & Jakubowicz, D. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350902 · Cited by 743 · cited 2×
“Two previous studies have examined the relationship between the reduction of hyperinsulinemia and ovarian steroidogenesis in response to a GnRH agonist (5, 68 ).”
BackgroundBARBIERI, R. L., MAKRIS, A., RANDALL, R. W., DANIELS, G., KISTNER, R. W., & RYAN, K. J. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-62-5-904 · Cited by 630
DUNAIF, A., GRAF, M., MANDELI, J., LAUMAS, V., & DOBRJANSKY, A. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-65-3-499 · Cited by 586
Evidence for Distinctive and Intrinsic Defects in Insulin Action in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Shelley, D. R., Green, G., Dobrjansky, A., & Licholai, T. (1992) · Diabetes · doi:10.2337/diab.41.10.1257 · Cited by 546
Dunaif, A., Scott, D., Finegood, D., Quintana, B., & Whitcomb, R. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.9.8784087 · Cited by 524 · cited 4×
“More recently, troglitazone was shown to improve defects in b-cell function in subjects with IGT (23) and to lower androgen levels in women with PCOS ( 25 ).”
BackgroundResultInfluentialCoronary Heart Disease Risk Factors in Women With Polycystic Ovary Syndrome
Talbott, E., Guzick, D., Clerici, A., Berga, S., Detre, K., Weimer, K., & Kuller, L. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.7.821 · Cited by 504
EHRMAN, D. A., BARNES, R. B., & ROSENFIELD, R. L. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-3-322 · Cited by 502
Self-citationDunaif, A. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.3.942 · Cited by 450 · cited 1×
“The insulin resistance is typically profound (2, 5, 7) and acts conjointly with alterations in b-cell function (7, 8 ) to impart a high risk for the development of early-onset noninsulin-dependent diabetes mellitus (NIDDM) (5‐7, 9, 10).”
BackgroundEhrmann, D. A., Sturis, J., Byrne, M. M., Karrison, T., Rosenfield, R. L., & Polonsky, K. S. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118064 · Cited by 426
Self-citationPrehepatic Insulin Production in Man: Kinetic Analysis Using Peripheral Connecting Peptide Behavior*
EATON, R. P., ALLEN, R. C., SCHADE, D. S., ERICKSON, K. M., & STANDEFER, J. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-51-3-520 · Cited by 363 · cited 1×
“These parameters were derived by application of a two-compartment model of C peptide distribution proposed by Eaton et al. ( 45 ).”
MethodPolonsky, K. S., Licinio-Paixao, J., Given, B. D., Pugh, W., Rue, P., Galloway, J., Karrison, T., & Frank, B. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112308 · Cited by 359 · cited 1×
“These parameters were used to derive, in each 15-min interval between blood sampling, the ISR from the plasma C peptide concentrations by deconvolution as previously described ( 46 ).”
MethodSelf-citationLeahy, J. L., Bonner-Weir, S., & Weir, G. C. (1992) · Diabetes Care · doi:10.2337/diacare.15.3.442 · Cited by 357
Ibañez, L., Potau, N., Virdis, R., Zampolli, M., Terzi, C., Gussinyé, M., Carrascosa, A., & Vicens-Calvet, E. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.6.8501168 · Cited by 341
Ehrmann, D. A., Cavaghan, M. K., Imperial, J., Sturis, J., Rosenfield, R. L., & Polonsky, K. S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.2.3722 · Cited by 336 · cited 3×
“The insulin resistance is typically profound (2, 5 , 7) and acts conjointly with alterations in b-cell function (7, 8) to impart a high risk for the development of early-onset noninsulin-dependent diabetes mellitus (NIDDM) (5‐7, 9, 10).”
BackgroundInfluentialSelf-citationCARA, J. F., & ROSENFIELD, R. L. (1988) · Endocrinology · doi:10.1210/endo-123-2-733 · Cited by 336
Self-citationBirdsall, M. A., Farquhar, C. M., & White, H. D. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-1-199701010-00005 · Cited by 327
Detection of Functional Ovarian Hyperandrogenism in Women with Androgen Excess
Ehrmann, D. A., Rosenfield, R. L., Barnes, R. B., Brigell, D. F., & Sheikh, Z. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207163270304 · Cited by 327 · cited 3×
“Fifteen women with hyperandrogenemia [plasma free testosterone, .10 pg/mL (34.6 pmol/L)] ( 26 ) and IGT (2 h plasma glucose concentration, 140 ‐199 mg/dL during OGTT) were recruited.”
BackgroundMethodInfluentialSelf-citationInsulin Resistance, Glucose Intolerance and Hyperinsulinemia in Patients with Hypertension
Swislocki, A. L. M., Hoffman, B. B., & Reaven, G. M. (1989) · American Journal of Hypertension · doi:10.1093/ajh/2.6.419 · Cited by 316
Pituitary-Ovarian Responses to Nafarelin Testing in the Polycystic Ovary Syndrome
Barnes, R. B., Rosenfield, R. L., Burstein, S., & Ehrmann, D. A. (1989) · New England Journal of Medicine · doi:10.1056/nejm198903023200904 · Cited by 311 · cited 1×
“Plasma levels of 17-progesterone, androstenedione, and DHEA were determined by RIA after these steroids had been chromatographically purified as previously reported ( 39 ).”
MethodSelf-citationFactors Responsible for Impaired Fibrinolysis in Obese Subjects and NIDDM Patients
McGill, J. B., Schneider, D. J., Arfken, C. L., Lucore, C. L., & Sobel, B. E. (1994) · Diabetes · doi:10.2337/diab.43.1.104 · Cited by 310 · cited 1×
“Increased concentrations of PAI-1 have been observed in subjects with insulin-resistant states, including diabetes ( 69 ), obesity (70), hypertension (71), and PCOS (15, 72).”
BackgroundSelf-citationAlessi, M. C., Juhan-Vague, I., Kooistra, T., Declerck, P. J., & Collen, D. (1988) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646997 · Cited by 289
Velazquez, E. M., Mendoza, S. G., Wang, P., & Glueck, C. J. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90066-4 · Cited by 249 · cited 1×
“Weight loss (70, 73) and treatment with metformin ( 74 ) have both been shown to decrease circulating concentrations of insulin as well as PAI-1.”
BackgroundDefects in beta-cell function in functional ovarian hyperandrogenism
O'Meara, N. M. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.5.1241 · Cited by 245
Self-citationCharacterization of Seven C-peptide Antisera
Faber, O. K., Binder, C., Markussen, J., Heding, L. G., Naithani, V. K., Kuzuya, H., Blix, P., Horwitz, D. L., & Rubenstein, A. H. (1978) · Diabetes · doi:10.2337/diab.27.1.s170 · Cited by 229
Folsom, A. R., Qamhieh, H. T., Wing, R. R., Jeffery, R. W., Stinson, V. L., Kuller, L. H., & Wu, K. K. (1993) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.13.2.162 · Cited by 225
Dysregulation of cytochrome P450c17α as the cause of polycystic ovarian syndrome
Rosenfield, R., Barnes, R., Cara, J., & Lucky, A. (1991) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(91)90373-d · Cited by 222
Cavaghan, M. K., Ehrmann, D. A., Byrne, M. M., & Polonsky, K. S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119562 · Cited by 216
Self-citationGuzick, D. S., Talbott, E. O., Sutton-Tyrrell, K., Herzog, H. C., Kuller, L. H., & Wolfson, S. K. (1996) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(96)70665-8 · Cited by 212
Sampson, M., Kong, C., Patel, A., Unwin, R., & Jacobs, H. S. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.00863.x · Cited by 186 · cited 1×
“Increased concentrations of PAI-1 have been observed in subjects with insulin-resistant states, including diabetes (69), obesity (70), hypertension (71), and PCOS (15, 72 ).”
BackgroundInduction of Plasminogen Activator Inhibitor Type-1 (PAI-1) by Proinsulin and Insulin In Vivo
Nordt, T. K., Sawa, H., Fujii, S., & Sobel, B. E. (1995) · Circulation · doi:10.1161/01.cir.91.3.764 · Cited by 185
Self-citationDetermination of tissue plasminogen activator and its "fast" inhibitor in plasma.
Chmielewska, J., & Wiman, B. (1986) · Clinical Chemistry · doi:10.1093/clinchem/32.3.482 · Cited by 183
Schneider, D. J., & Sobel, B. E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.22.9959 · Cited by 161 · cited 1×
“Insulin has been shown to directly augment expression of PAI-1 in vivo and in vitro ( 19 , 22, 75).”
BackgroundSelf-citationAndersen, P., Seljeflot, I., Abdelnoor, M., Arnesen, H., Dale, P. O., Løvik, A., & Birkeland, K. (1995) · Metabolism · doi:10.1016/0026-0495(95)90118-3 · Cited by 156 · cited 1×
“Weight loss (70, 73 ) and treatment with metformin (74) have both been shown to decrease circulating concentrations of insulin as well as PAI-1.”
BackgroundIntravenous Glucose Tolerance Test-Derived Insulin Sensitivity Changes during the Menstrual Cycle*
Valdés, C. T., & Elkind-Hirsch, K. E. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-3-642 · Cited by 146 · cited 1×
“Because of the possible effect of variations in insulin secretion ( 29 , 30) and ovarian function at different phases of the menstrual cycle, women were studied in the follicular phase (days 1‐ 8) of the cycle or after 2 or more months of amenorrhea.”
BackgroundIbrahimi, A., Teboul, L., Gaillard, D., Amri, E., Ailhaud, G. P., Young, P. W., Cawthorne, M. A., & Grimaldi, P. A. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09853-0 · Cited by 137
O'Meara, N. M., Sturis, J., Van Cauter, E., & Polonsky, K. S. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116560 · Cited by 132 · cited 4×
“The latter is expressed quantitatively by the improvement in normalized spectral power for insulin secretion (5.9 6 1.1 posttreatment vs. 4.3 6 0.8 pretreatment; P , 0.05) ( 34 ).”
BackgroundMethodInfluentialSelf-citationRosenfield, R. L., Barnes, R. B., & Ehrmann, D. A. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.6.7989476 · Cited by 131 · cited 1×
“Such a correlation was not demonstrable for individual steroids, possibly because the conversion of androstenedione to testosterone is enhanced in PCOS ( 66 , 67).”
BackgroundSelf-citationPasquali, R., Casimirri, F., Venturoli, S., Antonio, M., Morselli, L., Reho, S., Pezzoli, A., & Paradisi, R. (1994) · Metabolism · doi:10.1016/0026-0495(94)90118-x · Cited by 120 · cited 1×
“All study subjects were obese, and most were markedly so [mean body mass index (BMI), 39.9 6 1.4 kg/m2; range, 32.0 ‐ 47.3 kg/m2; Table 1]. Because alterations in body fat distribution can affect insulin sensitivity independently of body weight ( 49 ), precise assessment of regional fat distribution was made by dual e…”
BackgroundInfluentialEntrainment of pulsatile insulin secretion by oscillatory glucose infusion.
Sturis, J., Cauter, E. V., Blackman, J. D., & Polonsky, K. S. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115015 · Cited by 106 · cited 1×
“respond to repetitive increases and decreases in glucose with parallel changes in insulin secretion) is affected by troglitazone, a 20% glucose solution was administered in an oscillatory pattern with a period of 144 min, as previously described (34, 35 ).”
MethodSelf-citationMenstrual cyclicity has a profound effect on glucose homeostasis.
Diamond, M. P., Simonson, D. C., & DeFronzo, R. A. (1989) · Fertility and Sterility · doi:10.1016/s0015-0282(16)60842-7 · Cited by 98
Hemostatic and metabolic variables in women with polycystic ovary syndrome
Dahlgren, E., Janson, P. O., Johansson, S., Lapidus, L., Lindstedt, G., & Tengborn, L. (1994) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(94)90386-7 · Cited by 98
Berkowitz, K. M., Peters, R. K., Kjos, S. L., Goico, J., Marroquin, A., Dunn, M. E., Xiang, A. H., Azen, S. P., & Buchanan, T. A. (1996) · Diabetes · doi:10.2337/diab.45.11.1572 · Cited by 95 · cited 2×
“It is important to note that our current and previous (23) finding of improved b-cell function in IGT contrasts with the results of a recent trial of similar design in which women with IGT and a prior history of gestational diabetes were treated with troglitazone ( 60 ).”
BackgroundResultMoll, G., ROSENFIEL, R. L., & Helke, J. (1981) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-52-5-868 · Cited by 90 · cited 1×
“The free fraction of plasma testosterone and the concentration of sex hormone-binding globulin (SHBG) were measured by a competitive protein binding assay as previously described ( 38 ).”
MethodAnglés‐Cano, E. (1986) · Analytical Biochemistry · doi:10.1016/0003-2697(86)90082-5 · Cited by 89
Peroxisome proliferator-activated receptors A link between endocrinology and nutrition?
Keller, H., & Wahli, W. (1993) · Trends in Endocrinology and Metabolism · doi:10.1016/1043-2760(93)90048-j · Cited by 85
Masuda, K., Okamoto, Y., Tsuura, Y., Kato, S., Miura, T., Tsuda, K., Horikoshi, H., Ishida, H., & Seino, Y. (1995) · Diabetologia · doi:10.1007/bf02369349 · Cited by 77
White, D., Leigh, A., Wilson, C. A., Donaldson, A., & Franks, S. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb02665.x · Cited by 68
Sturis, J., Polonsky, K. S., Shapiro, E. T., Blackman, J. D., O’Meara, N., & Cauter, E. V. (1992) · Diabetologia · doi:10.1007/bf00400263 · Cited by 60
Self-citationInsulin Resistance and Ovarian Hyperandrogenism
Dunaif, A. E. (1992) · The Endocrinologist · doi:10.1097/00019616-199207000-00007 · Cited by 52
17‐Hydroxyprogesterone response to buserelin testing in the polycystic ovary syndrome
Şahin, Y., & Keleştimur, F. (1993) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1993.tb01767.x · Cited by 43
Prevalence of and Etiological Factors in Polycystic Ovarian Syndrome
Franks, S., & White, D. M. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb43859.x · Cited by 41
Brandes, R., Arad, R., & Bar‐Tana, J. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02082-9 · Cited by 21
Barbieri, R. L. (1992) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(11)90598-5 · Cited by 18
Cited by
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis*
Dunaif, A. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0318 · Cited by 2,458
Ehrmann, D. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041536 · Cited by 1,881
Self-citationRosenfield, R. L., & Ehrmann, D. A. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1104 · Cited by 1,603
Self-citationMonocyte chemoattractant protein 1 in obesity and insulin resistance
Sartipy, P., & Loskutoff, D. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1133870100 · Cited by 1,201
Metadata
- Authors
- Ehrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S.
- Affiliations
- University of Chicago (US)
- University of Vermont (US)
- Corresponding author
- Ehrmann, David A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1997-07
- Volume
- 82
- Issue
- 7
- Pages
- 2108-2116
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2073637312
- Cited by
- 461
- References
- 67
- Citations by year
- 2025: 2 · 2024: 3 · 2022: 6 · 2021: 2 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 7 · 2015: 2 · 2014: 5 · 2013: 10 · 2012: 11
- FWCI
- 36.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k08dk002315-02)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-31842, DK 20595, DK-02315)
- NIH Clinical Center
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- troglitazone, polycystic ovary syndrome, insulin resistance, insulin secretion, beta-cell function, ovarian steroidogenesis, fibrinolysis, plasminogen activator inhibitor-1, tissue plasminogen activator, hyperinsulinemia, impaired glucose tolerance, insulin sensitizers, hyperandrogenemia, obese women, leuprolide
- MeSH terms
- Troglitazone, Adult, Androgens, Chromans, Female, Fibrinolysis, Glucose, Glucose Tolerance Test, Gonadotropins, Humans, Insulin, Insulin Resistance, Polycystic Ovary Syndrome, Thiazoles, Leuprolide, Plasminogen Activator Inhibitor 1, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.